MEDVi vs Novi: Which GLP-1 Provider Is Better?

By Iacob Pastina, Independent Researcher

53 providers verified independently·Independent research·How we rank →

Visit MEDVi - $179/mo→or find your match

Novi beats MEDVi overall, scoring 7.8/10 vs 7.7/10. Novi is more affordable at $133/mo vs $179/mo. Choose MEDVi for users who want a low entry price with oral and injectable co. Choose Novi for cash-pay patients who want compounded semaglutide or tirzepa.

A side-by-side look at MEDVi and Novi to help you decide. We compare them on:

•Starting price per month
•Our overall score, out of 10
•Medication type, brand-name or compounded
•Whether they accept insurance
•Who each one is best for

MEDVi

#20 of 53

7.7/10

MEDVi is a compounded GLP-1 telehealth platform offering both oral tablets and injectable semaglutide and tirzepatide, with micro-dosing options for side-effect-sensitive patients. $179/mo entry pricing, free shipping, and a streamlined intake, one of the broader compounded mixes among independent telehealth providers in 2026.

Visit MEDVi

Higher Rated

Novi

#12 of 53

7.8/10

Telehealth platform for compounded semaglutide and tirzepatide with month-to-month billing, six named clinicians on staff, and a 3-minute pre-approval quiz. Novi emphasizes 'all-in transparent' pricing, medication, supplies, unlimited clinician check-ins, dose adjustments, and weight-loss coaching are bundled with no add-on fees. Standard pricing is $174/mo semaglutide and $283/mo tirzepatide; promotional pricing on the offer landing drops to $99-$133/mo semaglutide and $149-$166/mo tirzepatide with $200 off advertised.

Visit Novi

Feature	MEDVi	Novi
Our Score	7.7/10	7.8/10
Starting Price	$179/mo	$133/mo
Medication Type	Both	Compounded
Insurance Accepted	No	No
Best For	Users who want a low entry price with oral and injectable compounded options	Cash-pay patients who want compounded semaglutide or tirzepatide on a no-commitment plan with named clinicians, unlimited check-ins, and aggressive promotional pricing as low as $99-$133/mo on the introductory offer
Watch out for	No brand-name Wegovy or Zepbound on the platform (the 2026 expansion added branded Ozempic only)	Compounded-only, no FDA-approved Wegovy, Zepbound, Ozempic, or Mounjaro through the platform; no Foundayo or oral GLP-1 formats
Ranking	#20	#12
Get started	Visit MEDVi	Visit Novi

Pros & Cons Compared

MEDVi

Pros

+One of the few compounded providers offering both oral tablets and injectable semaglutide
+Micro-dosing options available, can start at sub-standard doses for patients concerned about side effects
+Sleek onboarding experience with clear progress tracking through their patient portal
+$179/mo is competitive for a platform with both oral and injectable compounded formulations

Cons

−No brand-name Wegovy or Zepbound on the platform (the 2026 expansion added branded Ozempic only)
−No insurance accepted, and oral compounded semaglutide has less clinical data than injectable forms; you can switch to injectable anytime at no extra fee if results lag

Novi

Pros

+Six disclosed clinicians on staff, Daniel Funsch MD, Michael Wasef MD, Takashi Nakamura MD plus three nurse practitioners (Hastings NP, Clements NP, Vergara DNP), more named providers than most compounded-only platforms publish
+Month-to-month billing with no minimum commitment, cancel before any renewal date with no early-termination penalty
+Aggressive promotional pricing on the offer landing, $99-$133/mo compounded semaglutide and $149-$166/mo compounded tirzepatide with a $200 OFF intro discount
+Unlimited clinician check-ins, dose adjustments, and weight-loss coaching included at no additional cost
+Free 2-day shipping; same active ingredients as Wegovy/Ozempic and Mounjaro/Zepbound (semaglutide and tirzepatide respectively)
+100,000+ patients claimed and editorial coverage in Bloomberg, Forbes, and WebMD provide third-party signal

Cons

−Compounded-only, no FDA-approved Wegovy, Zepbound, Ozempic, or Mounjaro through the platform; no Foundayo or oral GLP-1 formats
−Founding year, headquarters city, and corporate ownership are not publicly disclosed
−Promotional $99-$133 pricing applies to the introductory offer landing only, standard rate after any qualifying intro period is $174-$283/mo (verify the renewal rate before enrolling)
−Once medication is dispensed/shipped, prescriptions cannot be returned or refunded, typical for compounded telehealth but worth understanding
−Lab requirements before prescribing are not disclosed on public pages, unclear whether baseline bloodwork is required
−Multiple landing pages (offer-v4, offer-v6-low) show different headline prices, which can create pricing confusion before checkout

Our Verdict

Novi edges out MEDVi with a score of 7.8/10 vs 7.7/10. If budget is your priority, Novi starts at $133/mo compared to MEDVi's $179/mo. MEDVi offers both brand-name and compounded medications, giving you more flexibility. Choose MEDVi if you want: users who want a low entry price with oral and injectable compounded options. Choose Novi if you want: cash-pay patients who want compounded semaglutide or tirzepatide on a no-commitment plan with named clinicians, unlimited check-ins, and aggressive promotional pricing as low as $99-$133/mo on the introductory offer.

Still undecided? Editor's Featured Pick

TrimRx

$149/mo · 7.8/10 · Compounded

If neither MEDVi nor Novi feels like the right fit, our featured pick across all 53 GLP-1 telehealth providers is TrimRx. It is not the highest-scored provider in our full rankings. We feature it for its low-friction value: a flat $149/mo that stays the same at every dose.

Visit TrimRx→Read our full TrimRx review